Abstract 399P
Background
Currently in Indonesia, colorectal cancer (CRC) is the third most commonly occurring cancer in men and the fourth in women. CRC is mostly diagnosed in the advanced stage, it’s probably caused by the difficulties in detecting colorectal cancer. Identifying risk factors of CRC is very crucial to prevent CRC. CRC risk is expected to rise continually due to dietary patterns, smoking, lack of physical activities, and other practices. This study describes the prevalence of risk factors for CRC in healthy residents of Suluhan village, Bangli District, Bali Province.
Methods
A pre-experimental cross-sectional study-based community was conduct on 18th – 19th May 2019 in Suluhan village to collect data from 77 healthy residents using validated questionnaire. We measured sociodemographic characteristics, physical activity, dietary habits, and lifestyle as risk factors of CRC. Analysis of data using chi-square with p-value ≤0.05 is categorized as significant.
Results
77 respondents were involved in this study with a mean age of 41.94 ± 9.448 years. The majority of participants were female (61 %). Mostly the residents didn’t know CRC (80.6%). The commonest risk factors for CRC among the participants were overconsumption of red meat (2 times/week and >3 times/week) (67.6 %), overweight and obesity (62.4 %), limited consumption of vegetables (62.3 %), low of physical activities (44.1%), smoking (28.6%), and limited consumption of diet fiber (10.4%). Lack of physical activity was found significantly higher in females (p = 0,000), otherwise smoking (p = 0,000) is higher in males.
Conclusions
We conclude that the highest risk factor of CRC in Suluhan village is the overconsumption of red meat, followed by overweight and obesity, limited consumption of vegetables, low physical activities, smoking, and limited consumption of diet fiber sequentially. Dietary and lifestyle risk factors for CRC are prevalent in Suluhan village and likely to increase CRC incidence if educational interventions are not implemented. Greater attention in improving residents’ knowledge of CRC risk is needed to prevent CRC in Suluhan village.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract